2.51
2.33%
-0.06
After Hours:
2.45
-0.06
-2.39%
Novabay Pharmaceuticals Inc stock is currently priced at $2.51, with a 24-hour trading volume of 332.16K.
It has seen a -2.33% decreased in the last 24 hours and a +2,888% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.64 pivot point. If it approaches the $2.48 support level, significant changes may occur.
Previous Close:
$2.57
Open:
$2.5
24h Volume:
332.16K
Market Cap:
$2.89M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.2397
EPS:
-10.47
Net Cash Flow:
$-5.04M
1W Performance:
-7.38%
1M Performance:
+2,888%
6M Performance:
+769.72%
1Y Performance:
+260.74%
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
Nov-15-17 | Reiterated | Laidlaw | Buy |
Jun-05-17 | Initiated | ROTH Capital | Buy |
Mar-27-17 | Initiated | Laidlaw | Buy |
Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
Dec-14-15 | Reiterated | Maxim Group | Buy |
Apr-30-15 | Resumed | Maxim Group | Buy |
Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NioBay Announces Election of Directors
GlobeNewswire Inc.
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today? - MSN
MSN
StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50 Day Moving Average of $0.00 - Defense World
Defense World
NOVABAY PHARMACEUTICALS INC Trade Ideas — GETTEX:B9P0 — TradingView - TradingView
TradingView
NOVABAY PHARMAC. DL-,01 Trade Ideas — BER:B9P0 — TradingView - TradingView
TradingView
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Novabay Pharmaceuticals Inc (NBY) Revenue 2024
NBY reported a revenue (TTM) of $14.64 million for the quarter ending September 30, 2023, a +5.08% rise year-over-year.
Novabay Pharmaceuticals Inc (NBY) Net Income 2024
NBY net income (TTM) was -$13.74 million for the quarter ending September 30, 2023, a -436.64% decrease year-over-year.
Novabay Pharmaceuticals Inc (NBY) Cash Flow 2024
NBY recorded a free cash flow (TTM) of -$5.04 million for the quarter ending September 30, 2023, a +48.97% increase year-over-year.
Novabay Pharmaceuticals Inc (NBY) Earnings per Share 2024
NBY earnings per share (TTM) was -$7.27 for the quarter ending September 30, 2023, a -24.70% decline year-over-year.
About Novabay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Cap:
|
Volume (24h):